Tobira Therapeutics Inc. (NASDAQ:TBRA) shares hit a new 52-week low during trading on Tuesday . The company traded as low as $4.14 and last traded at $4.26, with a volume of 606,419 shares trading hands. The stock had previously closed at $4.50.

A number of research analysts recently commented on TBRA shares. Zacks Investment Research raised Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 price target for the company in a report on Saturday, April 23rd. HC Wainwright restated a “buy” rating on shares of Tobira Therapeutics in a research note on Tuesday, June 28th. Leerink Swann restated a “buy” rating and set a $18.00 price objective on shares of Tobira Therapeutics in a research note on Tuesday, May 10th. Cowen and Company restated a “buy” rating on shares of Tobira Therapeutics in a research note on Tuesday, May 10th. Finally, Cantor Fitzgerald cut Tobira Therapeutics to a “buy” rating and set a $19.00 price objective on the stock. in a research note on Monday. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $18.60.

The stock’s market cap is $78.08 million. The stock’s 50 day moving average is $11.54 and its 200 day moving average is $8.75.

Tobira Therapeutics (NASDAQ:TBRA) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.12. On average, equities analysts expect that Tobira Therapeutics Inc. will post ($2.49) EPS for the current fiscal year.

In other news, major shareholder A/S Novo sold 66,814 shares of the business’s stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $13.04, for a total value of $871,254.56. Following the sale, the insider now owns 2,073,022 shares of the company’s stock, valued at $27,032,206.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

An institutional investor recently bought a new position in Tobira Therapeutics stock. Marshall Wace LLP purchased a new stake in shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned approximately 0.57% of Tobira Therapeutics at the end of the most recent reporting period.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.